相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
Steven G. Gray et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Raffit Hassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S. Popat et al.
ANNALS OF ONCOLOGY (2020)
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
Morihito Okada et al.
CLINICAL CANCER RESEARCH (2019)
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine
Ursula A. Matulonis et al.
CLINICAL CANCER RESEARCH (2019)
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)
Michael P. Smolinski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Josine Quispel-Janssen et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Progress and challenges in Mesothelioma: From bench to bedside
Kevin G. Blyth et al.
RESPIRATORY MEDICINE (2018)
Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned
William D. Hedrich et al.
CLINICAL PHARMACOKINETICS (2018)
Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors
Leanna R. Staben et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
John M. Lambert et al.
ADVANCES IN THERAPY (2017)
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2016)
Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
Mark O'Hara et al.
IMMUNOTHERAPY (2016)
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Raffit Hassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Heather Donaghy
MABS (2016)
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Colin D. Weekes et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Immuno-oncology combinations: raising the tail of the survival curve
Sarnuel J. Harris et al.
CANCER BIOLOGY & MEDICINE (2016)
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
Joshua Seth Eaton et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2015)
Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?
Daniele Fanale et al.
ANALYTICAL CELLULAR PATHOLOGY (2015)
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Ira Pastan et al.
CANCER RESEARCH (2014)
Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
Stefan S. Kachala et al.
CLINICAL CANCER RESEARCH (2014)
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Laleh Amiri-Kordestani et al.
CLINICAL CANCER RESEARCH (2014)
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival
Gary Tozbikian et al.
PLOS ONE (2014)
Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Philipp Mueller et al.
CANCER IMMUNOLOGY RESEARCH (2014)
HER2 Amplification in Gastroesophageal Adenocarcinoma Correlation of Two Antibodies Using Gastric Cancer Scoring Criteria, H Score, and Digital Image Analysis With Fluorescence In Situ Hybridization
Oana M. Radu et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
Elliot L. Servais et al.
CLINICAL CANCER RESEARCH (2012)
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
R. Angelo de Claro et al.
CLINICAL CANCER RESEARCH (2012)
Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Danny Rischin et al.
CLINICAL CANCER RESEARCH (2011)
Mesothelial proteins are expressed in the human cornea
Katerina Jirsova et al.
EXPERIMENTAL EYE RESEARCH (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Folate Targeting Enables Durable and Specific Antitumor Responses from a Therapeutically Null Tubulysin B Analogue
Christopher P. Leamon et al.
CANCER RESEARCH (2008)
Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria
MW Khalil et al.
CHEMBIOCHEM (2006)
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
A Rump et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
